Tacrolimus lacrimal canaliculus plug (Ruitong Biotechnology)

他克莫司泪小管栓塞剂（瑞瞳生物）

Report date: 2026/03/04 20:01:44

Base Information

Drug NameTacrolimus lacrimal canaliculus plug (Ruitong Biotechnology)
Drug Alias NameRTP-008
ClassificationDrug and medical devices combination products
Mechanisms of ActionCalcineurin inhibitorsCytokines inhibitorsImmunosuppressants +[5] 
TargetsFK506 binding proteinCalcineurinCytokines +[4] 
Therapy Area/IndicationsXerophthalmia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Ruitong Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Ruitong Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsXerophthalmia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A